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ContraceptionAdults
Do not undertake or attempt any procedure unless you are, or have supervision from, a properly trained, experienced and competent person.
Always first explain the procedure to the patient and obtain his/her consent, in line with the policies of your employer or educational institution.
The use of needles to administer an injection poses a potential risk of 
needlestick injury to the healthcare professional (RCN, 2013). Employers are 
now required to eliminate the unnecessary use of sharps by providing 
medical devices that incorporate safety-engineered protection mechanisms 
(Health and Safety Executive, 2013; RCN, 2013; The European Council, 
2010). Many such safety devices are available, but your choice of equipment 
will depend on what is available locally. Ensure that an appropriate sharps 
disposal container is to hand, as close as possible to the area where the 
sharp is being used (Health and Safety Executive, 2013).    
If this is a repeat injection, ask the patient if she has noticed any side effects, 
or if she has any concerns. Ask about her bleeding pattern: it is normal for the 
contraceptive injection to cause changes, such as amenorrhea, irregular 
bleeding, spotting or heavy bleeding. If you are concerned that her symptoms  
may not be hormonally related, consider other causes, such as sexually 
transmitted infections, and whether further investigations (such as swabs or 
an assessment by the prescribing clinician) are needed. If the woman is 
experiencing other side-effects, ensure that she wants to continue with the 
injection and/or arrange for her to see the prescribing clinician for advice. 
Before beginning, check the patient’s identity, explain the procedure to the 
patient and gain verbal consent (NMC, 2015). Maintain the patient’s privacy 
and dignity throughout the procedure. Check that the injection has been 
prescribed for this patient.   
Equipment Preparation for the examination
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Women who have decided to use the contraceptive injection as their method of contraception need to attend for regular repeat injections, at specific intervals 
depending on which medication is used (FSRH, 2015). The prescribing clinician will have ensured that the woman meets the UK Medical Eligibility Criteria for 
the injection (RCOG, 2015), and she will have already received counselling about the advantages and disadvantages of the method. You must adhere to the 
Nursing and Midwifery Council’s Standards for Medicines Management (2010), which in this case includes awareness of the UK Medical Eligibility Criteria for 
the contraceptive injection (RCOG, 2015). 
The contraceptive injection contains progestogen (depo medroxyprogesterone acetate or DMPA). Its main mode of action is to inhibit ovulation. Progestogen 
also thickens the cervical mucus, preventing the sperm from swimming to the egg, and thins the endometrium, reducing the changes of a fertilised egg 
implanting in the uterus. 
The pages below show how to give one of the most widely used contraceptive injections, medroxyprogesterone acetate (Depo-Provera), which is given by 
intramuscular injection. Follow prescribing instructions to determine the correct interval between the injections. If the interval between the injections is greater 
than recommended, you must rule out pregnancy before giving the next injection, and advise the woman to use additional contraception (such as condoms) for 
a period after the injection. Guidance varies on how long this period should be: either 7 days (FSRH, 2015) or 14 days (BNF, 2016). If there is a risk of 
pregnancy, you can offer the woman emergency contraception, a bridging method, or a quick start on the injectable, as appropriate. She should also have a 
pregnancy test, no sooner than 3 weeks after the most recent episode of unprotected sexual intercourse (FSRH, 2015). The injection should not be given to a 
woman who is pregnant. 
In a woman under 18 years of age, DMPA may be used as a first-line contraceptive after all options have been discussed and considered unsuitable or 
unacceptable (FSRH, 2015). Women under 25 years old will have been told that the injection can cause reductions in bone density, but that bone density 
normally recovers after discontinuing the injections (NICE, 2015). Discuss the need for a calcium-rich diet and the importance of doing weight-bearing exercise 
in order to boost bone density. It is worth reminding the woman that if she wants to conceive within the next year, the injection would not be the contraceptive of 
choice as fertility can be delayed for up to 1 year after using it (FSRH, 2015).   
Carry out a re-evaluation of the risks and benefits of DMPA injections with women who want to continue to use this method for longer than two years (BNF, 
2016). 
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Giving a contraceptive injection Page 2
Offer the patient a chaperone Record the patient’s blood pressure
Record the patient’s weightRecord the patient’s height
Prepare the equipment Consider which injection site to use
Ask the patient if she would like a chaperone (NHS Clinical Governance 
Support Team, 2005). If she confirms that she is comfortable being alone in 
the room with you, ask her if she is happy for you to lock the door. 
Decontaminate your hands by washing with soap and water and drying 
thoroughly or using an alcohol-based hand rub. 
Record the patient’s blood pressure and monitor for hypertension, as blood 
pressure may rise due to the medication. Hypertension can increase the 
patient’s risk of adverse cardiovascular events. The prescribing clinician will 
have assessed these risks during the initial appointment. If the patient’s blood 
pressure is greater than 160/95 mmHg, do not give the injection; refer the 
patient for medical advice. 
If this is the patient’s first appointment, record the patient’s height as you will 
need this in order to determine her body mass index. 
Record the patient’s weight and record her body mass index. Use of DMPA is 
associated with weight gain, particularly in women under the age of 18 years 
of age with a BMI above 30 kg/m2. Women may gain more than 5% of their 
baseline body weight in the first 6 months of DMPA use (FSRH, 2015). Advise 
the patient about exercise and diet. Document all recorded measurements in 
the patient’s notes. 
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Do not undertake or attempt any procedure unless you are, or have supervision from, a properly trained, experienced and competent person.
Always first explain the procedure to the patient and obtain his/her consent, in line with the policies of your employer or educational institution.
You must follow the Nursing and Midwifery Council’s Standards for Medicines 
Management (2010) and local policies, including those on skin preparation 
and use of gloves. Check that the injection has been prescribed for your 
patient. Assemble the equipment; check that packaging is intact and not past 
its expiry date. Lay out the equipment on a cleaned trolley or tray, according 
to local policy and practice. Use a non-touch technique to avoid 
contamination and cross-infection.  
The injection should be given by deep intramuscular injection into the gluteal 
muscle, the deltoid muscle or the lateral thigh (NICE, 2015). It is most 
commonly given into the buttock, but in patients who are overweight or 
obese, the needle may not reach the muscle and the injection may instead be 
delivered into subcutaneous tissue (FSRH, 2015). A brief description of the 
available sites for intramuscular injections follows below; please refer to the 
clinicalskills.net procedures on intramuscular injections for more details.
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Giving a contraceptive injection Page 3
The dorsogluteal site has disadvantages Standing position for injecting into the dorsogluteal site
The ventrogluteal site
Decontaminate your hands
This site has the advantage that many practitioners in the UK are familiar with 
it, but it has several disadvantages, including the potential for damage to the 
sciatic nerve and the risk that the needle may not penetrate as far as the 
muscle in patients who are overweight or obese (FSRH, 2015). When using 
this site, you must check for flashback before giving the injection (see below). 
If using the dorsogluteal site, the patient can lie face down on the couch. The 
patient may prefer to stand, however. She will need to remove enough 
clothing to expose the site and rest her hands on the couch as shown. If the 
injection is being given on the right side, ask her to bend the right knee to lift 
the weight off her right leg and so relax the muscle to be injected.  
The ventrogluteal site is a safe injection site because it is relatively free of 
major nerves and blood vessels. Consider using this site if you have been 
trained to give injections in this region. In overweight or obese patients, 
however, there is still a risk that the needle may not penetrate as far as the 
muscle (FSRH, 2015). 
The vastus lateralis site is easy to access and there are few major blood 
vessels in the area. However, it can be painful and leave the patient in 
discomfort.
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Do not undertake or attempt any procedure unless you are, or have supervision from, a properly trained, experienced and competent person.
Always first explain the procedure to the patient and obtain his/her consent, in line with the policies of your employer or educational institution.
Decontaminate your hands and put on an apron and gloves, according to 
local policy. An apron is particularly important if you are not wearing uniform. 
Ask the patient to remove clothing to expose the chosen injection site.
Consider using the deltoid site if the patient is overweight or obese and you 
are concerned about whether the needle will reach the muscle tissue if you 
use the dorsogluteal or ventrogluteal sites (FSRH, 2015). 
The deltoid site
The vastus lateralis site
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Giving a contraceptive injection Page 4
Shake the syringe Attach the needle to the syringe
Administer the injection: first stretch the skin Insert the needle
Inject the medicine
Shake the syringe to ensure that the medicine is present in uniform amounts 
throughout the suspension. 
Tap the syringe gently to encourage air bubbles to rise (inset). Take the 
equipment to the patient, remove the cap from the syringe and attach the 
needle. Gently expel any air. Remove the protective cap from the needle. 
At your chosen injection site, stretch the skin 2 to 3 cm using your thumb, as 
shown. This technique is known as Z-tracking; it reduces pain and leakage 
from the injection site (Rodger and King, 2000; Nicoll and Hesby, 2002). 
When using this technique, it is not normally necessary to apply a plaster to 
the injection site after removing the needle. 
Using a darting motion, insert the needle at a 90º angle as this gives optimum 
opportunity to reach the target muscle. Insert the full length of the needle; do 
not leave a gap between the skin and the hub (Malkin, 2008). 
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Do not undertake or attempt any procedure unless you are, or have supervision from, a properly trained, experienced and competent person.
Always first explain the procedure to the patient and obtain his/her consent, in line with the policies of your employer or educational institution.
Slowly inject the medication (approximately 1 millilitre per 10 seconds) (Boyd, 
2013). The medication needs to be injected slowly in order to reduce the pain 
of the injection, and to allow the muscle fibres to stretch to accommodate the 
fluid.
To check for flashback, while maintaining skin traction, pull back on the 
plunger. If blood appears in the syringe, support the skin, withdraw the needle 
and start again from the beginning. If blood appears, the needle has entered 
a blood vessel. If you were to continue with the injection, it would enter the 
blood supply, not muscle. 
If injecting at the dorsogluteal site, check for flashback
It is only necessary to check for 
flashback if using the dorsogluteal site
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Giving a contraceptive injection Page 5
Remove the needle Dispose of the needle immediately
Check the site, apply pressure if required Dispose of equipment and wash your hands
Confirm the next injection date
Some authors recommend waiting 10 seconds before removing the needle, 
to avoid the medication leaking out (see, for example, Boyd (2013)). Follow 
local policy. Once the needle is out, immediately release the retracted skin, 
as this allows the medication to disperse evenly.  
Activate the safety device on the needle (inset) and immedi tely dispose of the 
needle into the sharps bin. 
Only apply pressure to the injection site with a dry gauze swab if it is oozing. 
Assist the patient into a comfortable position and give her privacy while she 
adjusts her clothing. 
Dispose of gloves, apron and other equipment according to local policy. Wash 
your hands. 
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Do not undertake or attempt any procedure unless you are, or have supervision from, a properly trained, experienced and competent person.
Always first explain the procedure to the patient and obtain his/her consent, in line with the policies of your employer or educational institution.
Advise the patient when her next injection will be due. As this method of 
contraception does not protect against sexually transmitted infections, offer 
the patient condoms according to local policy. 
Document on the medicines administration chart or computer that the 
medication has been given. Record the batch number, expiry date, injection 
site and route of injection.
Documentation
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